A phase-1 trial of CRISPR gene-editing technology demonstrated a significant reduction in blood cholesterol levels, exceeding 50%. CRISPR Therapeutics CEO Sam Kulkarni projects market release within five years, potentially impacting India's high cardiovascular disease rates. While medical professionals express optimism, widespread availability is still some years off.